We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Healthineers and Primary Health Care Enter Contract for In Vitro Diagnostics

By LabMedica International staff writers
Posted on 12 Nov 2018
Print article
Image: The Atellica Solution immunoassay and clinical chemistry analyzers (Photo courtesy of Siemens Healthineers).
Image: The Atellica Solution immunoassay and clinical chemistry analyzers (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers, marking the largest contract ever for in vitro diagnostics testing in the country.

The analyzers are integrated with Atellica Diagnostics IT solutions and will connect to the company’s strategic partner Inpeco’s FlexLab track for total lab automation to deliver a high throughput multi-disciplinary solution with capabilities that are transforming the clinical laboratory landscape across Australia.

Siemens Healthineers offers a wide portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Primary Health Care has a large presence in all mainland states in Australia with one in every three pathology samples taken in the country being tested in a Primary laboratory. The Siemens Healthineers technology will be rolled out in New South Wales, Queensland, Victoria and Western Australia.

The strategic engagement couples Primary’s expansive network of more than 2,300 national pathology collection sites with workflow improvement and expanded clinical capabilities from Siemens Healthineers to establish a new level of automated diagnostic delivery. Through deep analytics, and intelligent data and process management, Atellica Diagnostics IT software will provide Primary with improved visibility, flexibility and control over its entire operation. Siemens Healthineers and Inpeco SA will deliver this fully automated multidisciplinary solution that will vastly simplify clinical and operational workflows and help Primary achieve better outcomes at much lower costs.

“With the introduction of the Atellica Solution and the complementary, innovative offering of Atellica Diagnostics IT, we’ll turn what has been more than a decade of collaboration with Primary Health Care into an entirely new frontier for the Australian pathology industry,” said Sebastian D’Angelo, General Manager, Laboratory Diagnostics, Australia, Siemens Healthineers.

“This new collaboration will allow us to take Primary’s operational efficiencies to new heights,” said Wes Lawrence, Chief Executive of Pathology at Primary Health Care. “Thanks to this next-generation technology, we’re able to increase productivity, and focus more on value-adding lab activities and less on sample and instrument handling. In doing so, processes will be reduced and testing quality will be advanced, ultimately helping us increase cost savings and focus on the human impact of our work.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more